Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ovarian cancer test accuracy under review in 1,000 women

NCT ID NCT07539844

Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 3 times

Summary

This study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FRa testing, which may help guide future treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is surgical or biopsy sample from an adult female with tumoral High Grade Serous Ovarian Cancer.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Surgical or biopsy samples (Formalin Fixed Paraffin Embedded \[FFPE\]) with tumoral High Grade Serous Ovarian Cancer (HGSOC) material allowing the sectioning of serial slides for all the analyses. * Archival specimens should not be older than 5 years in order to control quality of the samples. * Specimens containing a minimum of 100 viable tumor cells. Exclusion Criteria: * Surgical or biopsy samples (FFPE) with insufficient quantity or quality (sampled more than 5 years ago and/or with less 100 viable tumor cells per section). * Tissue obtained following treatment with Mirvetuximab soravtansine or any other FRa targeted therapy. * Tissue obtained through fine needle aspirations or liquid specimens, or ascites

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High grade serous ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.C. Camargo Cancer Center - Rua Professor Antonio Prudente /ID# 280407

    RECRUITING

    São Paulo, São Paulo, 01509-900, Brazil

  • Biomakers /ID# 280318

    RECRUITING

    Buenos Aires, Buenos Aires, 1119, Argentina

  • Brazil - Generic Institution /ID# 287000

    RECRUITING

    São Paulo, Brazil

  • Fundacion Para La Investigacion Clinica Y Molecular Aplicada Del Cancer - Ficmac /ID# 282327

    RECRUITING

    Bogotá, Bogota D.C., 110111, Colombia

  • Fundacion Valle Del Lili /ID# 280794

    RECRUITING

    Cali, Valle del Cauca Department, 760016, Colombia

  • Hospital Italiano de Buenos Aires /ID# 280315

    RECRUITING

    Buenos Aires, Buenos Aires, 1181, Argentina

  • Instituto Alexander Fleming /ID# 281479

    RECRUITING

    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1426, Argentina

  • Instituto Nacional De Cancerologia /ID# 282312

    RECRUITING

    Bogota, Cundinamarca, 110411, Colombia

  • Mexico - Generic Institution /ID# 281927

    RECRUITING

    Mexico City, Mexico

  • Mexico - Generic Institution /ID# 281928

    RECRUITING

    Mexico City, Mexico

  • Mexico - Generic Institution /ID# 281930

    RECRUITING

    Mexico City, Mexico

  • Toronto General Hospital-University Health Network /ID# 282521

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.